---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005427"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:13:57.064396+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Profound Medical reports Q2 net loss of $15.7M; revenue flat at $2.2M; maintains 70-75% FY growth guidance

## Summary
- Net loss of $15.7M ($0.52/share) vs $6.9M ($0.28/share) in Q2 2024; revenue unchanged at $2.2M.
- Gross margin improved to 73% from 64% on manufacturing efficiencies; operating expenses rose to $15.4M from $9.3M.
- Same-store TULSA-PRO procedure volumes up 10% sequentially; pipeline of 80 new systems in qualifying stages.
- CEO cites short-term capital sales delays but reaffirms FY 2025 revenue growth target of 70-75% YoY.
- Cash position $35.2M; first commercial BPH treatment with TULSA-AI Volume Reduction Module conducted; full launch expected Q4 2025.

## SEC filing metadata
- accession: 0001171843-25-005427
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184325005427/0001171843-25-005427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184325005427/f8k_081425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005427
- JSON: https://secwatch.observer/filing/0001171843-25-005427.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005427.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.